Combined neprilysin and RAS inhibition for the failing heart: Straining the kidney to help the heart?

European Journal of Heart Failure

Volumn 17, Issue 5, 2015, Pages 468-471

  Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ANGIONEUROTIC EDEMA; BIOAVAILABILITY; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERVOLEMIA; MONOTHERAPY; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; ANTAGONISTS AND INHIBITORS; FEMALE; HEART STROKE VOLUME; KIDNEY; MALE; PATHOPHYSIOLOGY;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; FEMALE; HEART FAILURE; HUMANS; KIDNEY; MALE; NEPRILYSIN; STROKE VOLUME; TETRAZOLES;

EID: 84928470747     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.267     Document Type: Editorial

References (18)

1. Wilkins MR, Redondo J, Brown LA,. The natriuretic-peptide family. Lancet 1997; 349: 1307-1310.
2. Daniels LB, Maisel AS,. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
3. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K,. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-926.
4. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP,. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401-414.
5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
6. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ,. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395.
7. Merrill AJ,. Edema and decreased renal blood flow in patients with chronic congestive heart failure; evidence of forward failure as the primary cause of edema. J Clin Invest 1946; 25: 389-400.
8. Ljungman S, Laragh JH, Cody RJ,. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990; 39 (Suppl 4): 10-21.
9. Ruggenenti P, Remuzzi G,. Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. Eur Heart J 2011; 32: 2476-2478.
10. Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD,; for the PARAMOUNT Investigators. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015; 17: 510-517.
11. Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F, Jimenez Sosa A, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Trevisan R, Bossi A, Zaletel J, Remuzzi G,. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84: 164-173.
12. Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Dodesini AR, Trevisan R, Bossi A, Zaletel J, Remuzzi G,. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35: 2061-2068.
13. Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM,. Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 1987; 80: 670-674.
14. Jacobs EM, Vervoort G, Branten AJ, Klasen I, Smits P, Wetzels JF,. Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 1999; 29: 109-115.
15. Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, Dodesini AR, Trevisan R, Bossi A, Sampietro G, Capitoni E, Gaspari F, Rubis N, Ene-Iordache B, Remuzzi G,. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 2012; 23: 1717-1724.
16. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ,. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374: 543-550.
17. Zietse R, Derkx FH, Weimar W, Schalekamp MA,. Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. J Am Soc Nephrol 1995; 5: 2057-2066.
18. Ruggenenti P, Cravedi P, Remuzzi G,. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23: 1917-1928.